Actavis posts Q4 loss despite sales growth; Vanda awareness push raises expert ire; FDA, EMA plan closer work on safety;

@FiercePharma: Best-read on the site yesterday, back for Day 2: Actavis inks $25B deal for Forest in bid to build its brand stable. More | Follow @FiercePharma

@TracyStaton: BioMarin's $380K price tag on Vimizim is high, but far from the highest. More | Follow @TracyStaton

@EricPFierce: New York AG says Teva, Ranbaxy were on a collusion course with pay-to-delay deals. Yesterday's story | Follow @EricPFierce

@CarlyHFierce: Tops on FiercePharmaMarketing yesterday: Eisai's revved-up Belviq marketing starting to pay off, analysts say. Story | Follow @CarlyHFierce

> Despite strong sales growth, Actavis ($ACT) dipped into the red for the fourth quarter, thanks to restructuring and other charges; the company won't issue a 2014 forecast till its $25 billion Forest Laboratories ($FRX) buyout closes later this year. Report

> A Vanda Pharmaceuticals ($VNDA) disease awareness campaign for 24-hour sleep-wake disorder is raising eyebrows because it only affects a small percentage of blind people; Vanda recently won FDA approval for its Hetlioz treatment for the disorder. Report

> The FDA and its trans-Atlantic counterpart, the European Medicines Agency (EMA), plan to work more closely on medicines safety through regular collaborative meetings. Report

> Cipla inked a strategic partnership with Merck's ($MRK) Indian business to market the latter's HIV drug raltegravir in the country. Report

> Bayer HealthCare launched a global late-stage trial of Stivarga (regorafenib) in patients with colorectal cancer whose disease has spread to the liver. Report

Medical Device News

@FierceMedDev: S&N isn't the only one pursuing M&A to boost its sports medicine device offerings. Stryker is doing same. More | Follow @FierceMedDev

@MarkHFierce: Medtronic said its tiny wireless pacer has been implanted in its first U.S. patient. Release | Follow @MarkHFierce

@MichaelGFierce: BioMérieux's BioFire sets course for GI panel FDA clearance. Article | Follow @MichaelGFierce

> Syneron's revenue dips in Q4, but an aesthetic laser M&A deal gives a boost. Story

> A French outfit focused on medical imaging components is making inroads in China. Item

Biotech News

@FierceBiotech: Investigators: Personalized T cell attack spurs complete remissions of leukemia. Article | Follow @FierceBiotech

@JohnCFierce: Can a patient's dad succeed at Duchenne muscular dystrophy after all the biotech failures? Story | Follow @JohnCFierce

@DamianFierce: Raptor's Huntington's drug slowed the disease in a subset of patients, and that was enough to elate investors. News | Follow @DamianFierce

@EmilyMFierce: Gene therapy shows promise for treating heart attack victims. More from Scientific American | Follow @EmilyMFierce

> Is it news to you? Furiex really is up on the auction block. More

> Onconova hammered after top drug rigosertib flunks key PhIII study. Piece

Pharma Manufacturing News

> 13 drugmakers picked for FDA's special import perks. Story

> Cold-chain costs were halved in African vaccine campaign. Article

> Excipient makers jump on audits as new regs kick in. News

> GSK plant goes more than three years without plant injury. More

> West Pharmaceutical benefits from emerging market growth. Piece

> India pressures Merck and GSK on vaccine prices. Item

Vaccines News

> Dynavax's hep B vaccine plans derailed by European request for extra safety data. Report

> Novartis' Bexsero sparks debate about transatlantic vaccine approvals. Article

> WHO reports success in distributing vaccines at ambient temperatures. More

> CDC researchers say measles outbreaks cost U.S. health authorities up to $5M in 2011. News

> Chinese researchers see pandemic potential in bird flu virus reassortment. Story

> India is pushing GSK and Merck to slash the cost of HPV vaccines. Item

And Finally... Your smartphone keeps you connected to everything else. Why not your toothbrush? Report